Immune System News and Research

RSS

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

8 Oct 2009

Coeliac disease patients at risk of osteoporosis

People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

CSL Behring LEAD program invites grant requests from organizations assisting people with rare diseases

CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

7 Oct 2009

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Researchers show that DNA methylation plays a crucial role for cancer stem cells

During cell division, whether hematopoietic stem cells (HSCs) will develop into new stem cells (self-renewal) or differentiate into other blood cells depends on a chemical process called DNA methylation.

7 Oct 2009

IDF announces new social networking online website for people with PIDD

People with primary immunodeficiency diseases (PIDD) and their families will now be able to connect with one another and share their experiences through a new multidimensional social networking initiative, the Immune Deficiency Foundation (IDF) announced today. Primary immunodeficiency diseases are a group of rare, chronic illnesses, caused by hereditary or genetic defects in the immune system.

7 Oct 2009

Vaccination can lower the risks of allergy in children

Vaccination can lower children's risk of allergy. Cathleen Muche-Borowski and her coauthors present a clinical practice guideline for allergy prevention in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2009; 106[39]: 625-31).

7 Oct 2009

New study leads to the development of first prophylactic treatment for leishmania

Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year. Until recently, scientists were unsure exactly how the parasite survives inside human cells. That mystery has now been solved according to a new study published in Science Signaling by a team led by Dr. Martin Olivier - a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

7 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

GNC introduces clinically tested immune defense product

GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.

7 Oct 2009

Researchers make breakthrough in finding a vaccine against horse disease strangle

A research group at the Department of Microbiology, Swedish University of Agricultural Sciences (SLU) in Uppsala, Sweden has - in collaboration with J-I Flock's research group at the Karolinska Institutet medical university in Stockholm, the pharmacological company Intervacc AB, Stockholm and the Animal Health Trust in the UK - after many years of research made a breakthrough in finding a vaccine against the horse disease strangle.

7 Oct 2009

Health educator stresses the importance of sinus cleansing

With fall allergy season underway and Americans concerned about keeping their family safe from H1N1 and other flu viruses, health educator and fitness trainer Isabella "Betti" Jones is urging Americans to take a proactive, natural approach to staying healthy - the important step of daily sinus cleansing.

6 Oct 2009

pDCs promote growth and survival of malignant myeloma cells

Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor - to switch from defending the body against disease to shielding the myeloma cells from harm - Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.

6 Oct 2009

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

The winner of the 2009 EUROPEAN BIOTECHNICA AWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receives the lion’s share of the €100,000 prize money, which is awarded each year by Deutsche Messe AG and its partners. The aim of the award is to celebrate the achievements of innovative European companies in the field of biotechnology and the life sciences.

6 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Immune System News and Research

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Coeliac disease patients at risk of osteoporosis

Entest BioMedical applies for Phase II grant from National Cancer Institute

NCI awards $11.5 million grant to UAB for cervical cancer research

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

CSL Behring LEAD program invites grant requests from organizations assisting people with rare diseases

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Researchers show that DNA methylation plays a crucial role for cancer stem cells

IDF announces new social networking online website for people with PIDD

Vaccination can lower the risks of allergy in children

New study leads to the development of first prophylactic treatment for leishmania

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

GNC introduces clinically tested immune defense product

Researchers make breakthrough in finding a vaccine against horse disease strangle

Health educator stresses the importance of sinus cleansing

pDCs promote growth and survival of malignant myeloma cells

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News